Advancing the public health applications of Chlamydia trachomatis serology

Sarah C. Woodhall, Rachel J. Gorwitz, Stephanie J. Migchelsen, Sami L. Gottlieb, Patrick J. Horner, William M. Geisler, Catherine Winstanley, Katrin Hufnagel, Tim Waterboer, Diana L. Martin, Wilhelmina M. Huston, Charlotte A Gaydos, Carolyn Deal, Magnus Unemo, J. Kevin Dunbar, Kyle Bernstein

Research output: Contribution to journalArticle

Abstract

Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions including screening and treatment, and to assess new vaccine candidates. However, questions about the performance characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance development within this field. In this Personal View, we explore the available information about C trachomatis serology and propose several priority actions. These actions involve development of target product profiles to guide assay selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate assay development and evaluation, and development of technical and statistical methods for assay evaluation and analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public health community to align technological developments with their potential applications.

Original languageEnglish (US)
JournalThe Lancet Infectious Diseases
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Chlamydia trachomatis
Serology
Chlamydia Infections
Public Health
Eye Infections
Trachoma
Pelvic Inflammatory Disease
Blindness
Sexually Transmitted Diseases
Cicatrix
Epidemiology
Vaccines
Biomarkers
Incidence
Serum
Population

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Woodhall, S. C., Gorwitz, R. J., Migchelsen, S. J., Gottlieb, S. L., Horner, P. J., Geisler, W. M., ... Bernstein, K. (Accepted/In press). Advancing the public health applications of Chlamydia trachomatis serology. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(18)30159-2

Advancing the public health applications of Chlamydia trachomatis serology. / Woodhall, Sarah C.; Gorwitz, Rachel J.; Migchelsen, Stephanie J.; Gottlieb, Sami L.; Horner, Patrick J.; Geisler, William M.; Winstanley, Catherine; Hufnagel, Katrin; Waterboer, Tim; Martin, Diana L.; Huston, Wilhelmina M.; Gaydos, Charlotte A; Deal, Carolyn; Unemo, Magnus; Dunbar, J. Kevin; Bernstein, Kyle.

In: The Lancet Infectious Diseases, 01.01.2018.

Research output: Contribution to journalArticle

Woodhall, SC, Gorwitz, RJ, Migchelsen, SJ, Gottlieb, SL, Horner, PJ, Geisler, WM, Winstanley, C, Hufnagel, K, Waterboer, T, Martin, DL, Huston, WM, Gaydos, CA, Deal, C, Unemo, M, Dunbar, JK & Bernstein, K 2018, 'Advancing the public health applications of Chlamydia trachomatis serology', The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(18)30159-2
Woodhall, Sarah C. ; Gorwitz, Rachel J. ; Migchelsen, Stephanie J. ; Gottlieb, Sami L. ; Horner, Patrick J. ; Geisler, William M. ; Winstanley, Catherine ; Hufnagel, Katrin ; Waterboer, Tim ; Martin, Diana L. ; Huston, Wilhelmina M. ; Gaydos, Charlotte A ; Deal, Carolyn ; Unemo, Magnus ; Dunbar, J. Kevin ; Bernstein, Kyle. / Advancing the public health applications of Chlamydia trachomatis serology. In: The Lancet Infectious Diseases. 2018.
@article{d1172c37950a4e3683d88d56d8e3af15,
title = "Advancing the public health applications of Chlamydia trachomatis serology",
abstract = "Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions including screening and treatment, and to assess new vaccine candidates. However, questions about the performance characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance development within this field. In this Personal View, we explore the available information about C trachomatis serology and propose several priority actions. These actions involve development of target product profiles to guide assay selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate assay development and evaluation, and development of technical and statistical methods for assay evaluation and analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public health community to align technological developments with their potential applications.",
author = "Woodhall, {Sarah C.} and Gorwitz, {Rachel J.} and Migchelsen, {Stephanie J.} and Gottlieb, {Sami L.} and Horner, {Patrick J.} and Geisler, {William M.} and Catherine Winstanley and Katrin Hufnagel and Tim Waterboer and Martin, {Diana L.} and Huston, {Wilhelmina M.} and Gaydos, {Charlotte A} and Carolyn Deal and Magnus Unemo and Dunbar, {J. Kevin} and Kyle Bernstein",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/S1473-3099(18)30159-2",
language = "English (US)",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Advancing the public health applications of Chlamydia trachomatis serology

AU - Woodhall, Sarah C.

AU - Gorwitz, Rachel J.

AU - Migchelsen, Stephanie J.

AU - Gottlieb, Sami L.

AU - Horner, Patrick J.

AU - Geisler, William M.

AU - Winstanley, Catherine

AU - Hufnagel, Katrin

AU - Waterboer, Tim

AU - Martin, Diana L.

AU - Huston, Wilhelmina M.

AU - Gaydos, Charlotte A

AU - Deal, Carolyn

AU - Unemo, Magnus

AU - Dunbar, J. Kevin

AU - Bernstein, Kyle

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions including screening and treatment, and to assess new vaccine candidates. However, questions about the performance characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance development within this field. In this Personal View, we explore the available information about C trachomatis serology and propose several priority actions. These actions involve development of target product profiles to guide assay selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate assay development and evaluation, and development of technical and statistical methods for assay evaluation and analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public health community to align technological developments with their potential applications.

AB - Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions including screening and treatment, and to assess new vaccine candidates. However, questions about the performance characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance development within this field. In this Personal View, we explore the available information about C trachomatis serology and propose several priority actions. These actions involve development of target product profiles to guide assay selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate assay development and evaluation, and development of technical and statistical methods for assay evaluation and analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public health community to align technological developments with their potential applications.

UR - http://www.scopus.com/inward/record.url?scp=85049490900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049490900&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(18)30159-2

DO - 10.1016/S1473-3099(18)30159-2

M3 - Article

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

ER -